Objectives: We aim in our 3 years observational study to evaluate the predictive role of ILC2 in SSc patients.

Methods: We conducted an observational retrospective study on 52 patients with SSc fulfilling the 2013 ACR/EULAR classification criteria. Yearly clinical, laboratory and investigational data according to EUSTAR recommendations were collected. Blood samples collected between 15.09.2014 and 15.01.2015 were analyzed by flow cytometry and ILC2 counts were measured. The predictive value of ILC2 during a 3-year follow-up was analyzed using SPSS 21.0.

Results: 52 patients were included in the study, 78% female, 63% limited cutaneous SSc with a mean follow-up time of 2.85 ± 1.28 years. At baseline we have shown that circulating ILC2s are significantly increased compared to gender and age-matched healthy controls. Increased numbers of ILC2s significantly correlated with worsening of mRSS calculated by five point increase in mRSS or 25% increase from baseline ($p < 0.001$; 95% CI 1.39 – 3.26). ILC2 counts also correlated with 5% decrease of diffusion capacity of carbon monoxide (DLCO) during the follow-up time ($p < 0.0001$; 95% CI 1.83 – 3.49). Worsening of forced vital capacity (FVC) assessed as 5% decrease over 2 years was also significantly correlated with an increased number of ILC2s ($p < 0.0001$; 95% CI 1.27 – 3.04). In contrast, we did not find any correlation regarding increase in pulmonary arterial pressure assessed by echocardiography. Although new appearance of digital ulcers could not be predicted by ILC2 counts, increased numbers of ILC2s were correlated with digital ulcers at follow-up.

Conclusion: Here, we provide first evidence for a role of ILC2s as potential prognostic marker of disease progression in SSc.

Disclosure of Interests: Alina Soare: None declared, Stefanie Weber: None declared, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Jörg Distler Grant/research support from: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Paid instructor for: Boehringer Ingelheim, Speakers bureau: Boehringer Ingelheim, Andreas Ramming Grant/research support from: Pfizer, Novartis, Consultant of: Boehringer Ingelheim, Novartis, Gilead, Pfizer, Speakers bureau: Boehringer Ingelheim, Roche, Janssen

DOI: 10.1136/annrheumdis-2020-eular.6322

SAT0343

NUTRITIONAL STATUS OF SYSTEMIC SCLEROSIS PATIENTS: A PILOT STUDY

I. Szabo^{1,2}, A. Petcu², D. Chincinas³, V. Rednic³, M. M. Tamas^{1,2}, L. Muntean^{1,2}, I. Filipescu^{1,2}, S. P. Simon^{1,2}, C. Pamfil², S. Rednic^{1,2}. ¹County Emergency Clinical Hospital Cluj-Napoca, Rheumatology, Cluj-Napoca, Romania; ²University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Cluj-Napoca, Romania; ³Regional Institute of Gastroenterology and Hepatology "Octavian Fodor" Cluj-Napoca, Cluj-Napoca, Romania

Background: Gastrointestinal involvement (GI) in systemic sclerosis (SSc) is one of the major disease burdens. Its consequences on the nutritional status of SSc patients and their quality of life is poorly evaluated during routine check-ups. Since malnutrition is an important cause of morbidity and mortality, addressing this issue seems necessary.

Objectives: The aim of this study was to evaluate the risk of malnutrition in SSc patients and to identify potential associations between the risk of malnutrition and clinical features or laboratory parameters.

Methods: All patients aged >18 years old with a definite diagnosis of SSc according to the 2013 ACR/EULAR classification criteria from the EUSTAR Center 16 and ERN ReCONNECT cohort of the County Emergency Clinical Hospital Cluj-Napoca were included in the study. Patients with localized scleroderma, scleroderma sine scleroderma, overlap syndromes and mixed connective tissue disease were excluded. Clinical and laboratory data was collected from the EUSTAR database and medical charts. A telephone survey was conducted and patients were interviewed using the Malnutrition Universal Screening Tool (MUST) questionnaire.

Results: 75 patients were eligible for the study. Female to male ratio was 10:1 with an almost equal distribution among limited (57%) and diffuse (43%) SSc subtypes. The most prevalent autoantibodies were anti-TOPO-I and anti-centromere. GI symptoms were reported in 48.6% patients out of which 86% SSc patients underwent further evaluation by upper GI endoscopy. Abnormal endoscopic findings, such as esophagitis, Barrett esophagus and gastritis were identified in 80% patients. Most patients had a low risk of malnutrition (93%) with only a minority carrying a medium (6%) or high (1%) risk. No significant association was demonstrated between MUST score and the extent of cutaneous involvement (limited SSc versus diffuse SSc; $p=0.39$), presence of GI symptoms ($p=0.35$), presence of abnormal endoscopic findings ($p=0.45$) or presence of anemia ($p=0.83$).

Conclusion: The majority of SSc patients from this cohort exhibited a low risk of malnutrition. These results are contradictory to previous literature reports. A possible explanation is that the MUST score is a dynamic screening tool and therefore interviewing patients with a stable disease (outpatient care) versus patients with active disease (inpatient care) might lead to different results. Another limitation of this study is the small number of patients included. This is a pilot study. We aim to further extend the study population to the other EUSTAR cohorts and to prospectively evaluate these patients in an inpatient care setting.

References:

- [1] Dupont R et al. Impact of micronutrient deficiency & malnutrition in systemic sclerosis: Cohort study and literature review. *Autoimmun Rev*. 2018 Nov;17(11):1081-1089;
- [2] Caimmi C et al. Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis. *Clin Rheumatol*. 2018 Apr;37(4):987-997;
- [3] Türk I et al. Malnutrition, associated clinical factors, and depression in systemic sclerosis: a cross-sectional study. *Clin Rheumatol*. 2020 Jan;39(1):57-67.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6459

SAT0344

LIMITED JOINT MOBILITY OF HAND IN SYSTEMIC SCLEROSIS PATIENTS BY USING "PRAYER" AND "TABLE TOP" SIGNS

S. Uslu¹, S. Gulle², A. Koken Avsar², A. Karakas², S. B. Kocaer², T. Yüce Inel², Y. Erez², G. Can², İ. Sari², F. Onen², M. Birlik². ¹Ömer Halisdemir University Bor Physical Medicine and Rehabilitation, Training and Research Hospital, Department of Rheumatology, Niğde, Turkey; ²Dokuz Eylül University Faculty of Medicine, Department of Rheumatology, Izmir, Turkey

Background: Limited joint mobility (LJM) is a musculoskeletal disorder caused by flexion contractures of hand is a common complication in systemic sclerosis (SSc) patients. The distal parts of the upper limb (hands and fingers) is the most involved site in SSc.

Objectives: In this study, we aimed to evaluate LJM in SSc patients and to determine the relationship between the clinical features of the disease.

Methods: A total of 113 patients (>18 years old) diagnosed with diffuse cutaneous systemic sclerosis (DcSSc) and limited cutaneous systemic sclerosis (LcSSc) and 104 healthy controls were included in this study. LJM was evaluated with "prayer sign" and "table top sign" tests. LJM staging was done by Rosenbloom classification method(1, 2). LJM (+) and LJM (-) patients were compared in terms of demographic findings (gender, age and duration of disease), laboratory results (ESR, CRP, ANA, anti-topoisomerase I and anti-centromere) and modified Rodnan Skin Score (mRSS) results.

Results: In our study, a total of 113 patients diagnosed with SSc and 104 healthy controls with similar age and gender distribution were included. While LJM (+) was detected in 75 (66.4%) (LcSSc = 38, DcSSc = 37) of the patients diagnosed with SSc, LJM (mild) (+) was detected in 3 (2.8%) of the control group. One of these people had right 2nd DIF joint contracture due to osteoarthritis, and 1 patient was found to have simple contractures due to minor hand injury previously (Table 1). A statistically significant difference was observed in between LcSSc and DcSSc patients according to the presence of LJM ($p<0.001$) (Table 2). There was a moderate positivity relationship between LJM and mRSS (LcSSc: $r=0.449$ ve $p<0.001$, DcSSc: $r= 0.565$ ve $p<0.001$) (Figure 1).

Table 1. Comparison of demographic findings between SSc and Control group

	SSc Group (n=113)	Control Group (n=104)	p value
Age, year	57.02 ± 11.58	58.47 ± 11.26	0.061
Gender (F / M)	98 (86.7) / 15 (13.3)	65 (62.5) / 39 (37.5)	0.064
CRP (mg/L)	5.45 ± 5.39	2.14 ± 1.12	<0.001
ESR (mm/hr)	25.19 ± 18.9	14.46 ± 10.09	0.024
Smoking, n (%)			
Smoker	89 (78.8)	70 (67.3)	0.464
Non-Smoker	24 (21.2)	34 (32.7)	
LJM (Absent / Present)			
Present	75 (66.4)	3 (2.8)	<0.001
Absent	38 (33.6)	101 (97.2)	
Rosenbloom classification	LcSSc (n=71) (%)	DcSSc (n=42) (%)	Total (n=113) (%)
Normal	46.5	11.9	33.6
Mild	22.5	14.3	19.5
Moderate	23.9	33.3	27.4
Severe	7.1	40.5	19.5